Anticancer drug discovery by targeting cullin neddylation

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Protein neddylation is a post-translational modification essential for Cullin-RING E3 ubiquitin ligase (CRL) activity.
• CRL dysfunction is implicated in cancer development and progression.
• Targeting the neddylation pathway presents a promising strategy for novel anti-cancer drug discovery.

Purpose of the Study:

• To provide a comprehensive overview of the discovery efforts for neddylation inhibitors.
• To summarize the current understanding of protein neddylation and its regulatory cascade.
• To discuss strategies for targeting protein-protein interactions within the neddylation pathway.

Main Methods:

• Literature review of protein neddylation mechanisms and inhibitors.
• Summary of reported chemical inhibitors targeting neddylation enzymes.
• Discussion of structure-based drug design approaches for neddylation inhibitors.

Main Results:

• Significant advancements in preclinical and clinical development of neddylation inhibitors over the past decade.
• Identification and characterization of various chemical inhibitors targeting key enzymes in the neddylation cascade.
• Exploration of structure-based strategies to inhibit protein-protein interactions in neddylation.

Conclusions:

• Neddylation inhibition is a viable therapeutic strategy for cancer treatment.
• Continued research into neddylation inhibitors holds promise for developing new anti-cancer drugs.
• Structure-based drug design and screening approaches are crucial for discovering novel neddylation inhibitors.